Related Experiment Video

Updated: Apr 22, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K

Impact of MDM2 single nucleotide polymorphism on oral squamous cell carcinoma risk

Jian-Li Xie1, Jing-Lei Yang, De-Sheng Liu

  • 1School of Stomatology, Shandong University, Wenhuaxi Road, Jinan, 250012, Shandong, China.

Cell Biochemistry and Biophysics
|October 18, 2014
PubMed

Insights

The Mouse Double Minute 2 (MDM2) 309 T>G polymorphism does not significantly affect oral squamous cell carcinoma (OSCC) risk. This meta-analysis found no increased or decreased susceptibility to OSCC associated with this genetic variation.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Mouse Double Minute 2 (MDM2) is a key regulator of p53, a tumor suppressor.
  • The MDM2 309 T>G polymorphism's role in oral squamous cell carcinoma (OSCC) susceptibility is unclear.
  • Previous studies on this association yielded conflicting results.

Purpose of the Study:

  • To conduct a meta-analysis evaluating the association between the MDM2 309 T>G polymorphism and OSCC susceptibility.
  • To clarify the conflicting evidence regarding this genetic polymorphism and cancer risk.

Main Methods:

  • A systematic literature search was performed on PubMed and Embase.
  • Five case-control studies involving 1,369 OSCC cases and 2,167 controls were included.
  • Statistical analysis used odds ratios (OR) with 95% confidence intervals (CI), heterogeneity tests, sensitivity analysis, and publication bias assessment.

Main Results:

  • The meta-analysis revealed no significant association between the MDM2 309 T>G polymorphism and OSCC risk across all genetic models.
  • Subgroup analysis in Asian populations also showed no significant risk.
  • No substantial heterogeneity or publication bias was detected.

Conclusions:

  • The MDM2 309 T>G polymorphism does not appear to significantly contribute to OSCC susceptibility.
  • Further research may be warranted, but current evidence suggests a lack of association.

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.4K
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

15.7K

Related Concept Videos

Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
5.3K
Mismatch Repair01:36

Mismatch Repair

Overview
37.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.1K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
152